Cyber Monday Deal: Up to 60% off InvestingProCLAIM SALE

89bio Inc (ETNB)

NASDAQ
Currency in USD
9.46
+0.47(+5.23%)
Real-time Data
ETNB Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
8.999.71
52 wk Range
7.0016.63
Key Statistics
Edit
Prev. Close
8.99
Open
9.01
Day's Range
8.99-9.71
52 wk Range
7-16.63
Volume
240.22K
Average Vol. (3m)
697K
1-Year Change
7.02%
Book Value / Share
unlockUnlock
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ETNB Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
30.12
Upside
+218.39%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

89bio Inc Company Profile

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

89bio Inc SWOT Analysis


Strategic Positioning
Learn about pegoza's potential synergies with GLP-1 therapies and its promising efficacy in advanced MASH stages, positioning 89Bio for future growth
Financial Outlook
Analyst price targets for 89Bio range from $12 to $29, reflecting varied perspectives on pegoza's market potential and development progress
Market Dynamics
Delve into the competitive MASH treatment landscape, where pegoza's unique benefits could differentiate it from emerging GLP-1 therapies
Pegoza's Promise
Explore 89Bio's lead candidate pegozafermin, showing potential in treating Metabolic Associated Steatohepatitis (MASH) with antifibrotic and cardiometabolic benefits
Read full SWOT analysis

Compare ETNB to Peers and Sector

Metrics to compare
ETNB
Peers
Sector
Relationship
P/E Ratio
−3.9x−5.8x−0.7x
PEG Ratio
0.070.050.00
Price / Book
3.0x2.7x2.6x
Price / LTM Sales
-33.0x3.2x
Upside (Analyst Target)
228.1%158.9%44.5%
Fair Value Upside
Unlock9.3%6.6%Unlock

Analysts' Recommendations

7 Buy
2 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 30.13

(+218.45% Upside)

People Also Watch

19.58
TVTX
+4.09%
91.98
DAVE
-6.79%
79.55
PRAX
-0.77%

FAQ

What Is the 89bio (ETNB) Stock Price Today?

The 89bio stock price today is 9.46

What Stock Exchange Does 89bio Trade On?

89bio is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for 89bio?

The stock symbol for 89bio is "ETNB."

What Is the 89bio Market Cap?

As of today, 89bio market cap is 1.11B.

What is 89bio Earnings Per Share?

The 89bio EPS is -3.01.

What Is the Next 89bio Earnings Date?

89bio will release its next earnings report on Mar 19, 2025.

From a Technical Analysis Perspective, Is ETNB a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.